Mind Medicine (MindMed) Yönetim

Yönetim kriter kontrolleri 3/4

Mind Medicine (MindMed) CEO'su Rob Barrow, Jun2021 tarihinde atandı, in görev süresi 3.42 yıldır. in toplam yıllık tazminatı $ 2.14M olup, şirket hissesi ve opsiyonları dahil olmak üzere 27.9% maaş ve 72.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.27% ine doğrudan sahiptir ve bu hisseler € 1.45M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.3 yıl ve 3.1 yıldır.

Anahtar bilgiler

Rob Barrow

İcra Kurulu Başkanı

US$2.1m

Toplam tazminat

CEO maaş yüzdesi	27.9%
CEO görev süresi	3.4yrs
CEO sahipliği	0.3%
Yönetim ortalama görev süresi	2.3yrs
Yönetim Kurulu ortalama görev süresi	3.1yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Rob Barrow'un ücretlendirmesi Mind Medicine (MindMed)'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$98m
Jun 30 2024	n/a	n/a	-US$102m
Mar 31 2024	n/a	n/a	-US$125m
Dec 31 2023	US$2m	US$599k	-US$96m
Sep 30 2023	n/a	n/a	-US$77m
Jun 30 2023	n/a	n/a	-US$75m
Mar 31 2023	n/a	n/a	-US$63m
Dec 31 2022	US$5m	US$672k	-US$57m
Sep 30 2022	n/a	n/a	-US$69m
Jun 30 2022	n/a	n/a	-US$69m
Mar 31 2022	n/a	n/a	-US$98m
Dec 31 2021	US$12m	US$350k	-US$93m

Tazminat ve Piyasa: Rob 'nin toplam tazminatı ($USD 2.14M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.03M ).

Tazminat ve Kazançlar: Rob 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Rob Barrow (35 yo)

3.4yrs

Görev süresi

US$2,143,133

Tazminat

Mr. Robert Barrow, also known as Rob, serves as Chief Executive Officer at Mind Medicine (MindMed) Inc since June 9, 2021 and serves a its Director since December 13, 2021. He served as Chief Development O...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Robert Barrow	CEO & Director	3.4yrs	US$2.14m	0.27% € 1.5m
Daniel Karlin	Chief Medical Officer	3.8yrs	US$1.04m	0.32% € 1.7m
Miriam Wernli	Executive President	4.3yrs	US$2.66m	0.16% € 844.2k
Scott Freeman	Co-Founder & Clinical Advisor	no data	US$501.19k	Veri yok
Leonard Latchman	Co-founder	no data	Veri yok	Veri yok
Carrie Liao	VP & Chief Accounting Officer	2yrs	Veri yok	0.060% € 319.4k
Mark Sullivan	Chief Legal Officer & Corporate Secretary	1.6yrs	Veri yok	0.072% € 380.4k
Francois Lilienthal	Chief Commercial Officer	2.6yrs	Veri yok	Veri yok
Stephanie Fagan	Chief Corporate Affairs Officer	less than a year	Veri yok	Veri yok
Gregg Pratt	Chief Regulatory & Quality Assurance Officer	no data	Veri yok	Veri yok

2.3yrs

Ortalama Görev Süresi

55.5yo

Ortalama Yaş

Deneyimli Yönetim: MMQ 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Robert Barrow	CEO & Director	2.9yrs	US$2.14m	0.27% € 1.5m
Carol Vallone	Independent Chairperson	3.2yrs	US$196.20k	0.018% € 94.7k
David Gryska	Independent Director	1.4yrs	US$179.01k	0.011% € 58.6k
Suzanne Bruhn	Independent Director	2.3yrs	US$148.70k	0.017% € 88.3k
Robert Malenka	Chair of Scientific Advisory Board	3.7yrs	Veri yok	Veri yok
Robert Dworkin	Member of Scientific Advisory Board	3.3yrs	Veri yok	Veri yok
Maurizio Fava	Member of Scientific Advisory Board	3.4yrs	Veri yok	Veri yok
Andreas Krebs	Independent Vice Chairman	3.2yrs	US$186.20k	0.016% € 84.3k
Roger Crystal	Independent Director	2.3yrs	US$148.70k	0.017% € 88.3k
Nzinga Harrison	Member of Scientific Advisory Board	less than a year	Veri yok	Veri yok
Peter Bergethon	Member of Scientific Advisory Board	3.4yrs	Veri yok	Veri yok
Maria Oquendo	Member of Scientific Advisory Board	3yrs	Veri yok	Veri yok

3.1yrs

Ortalama Görev Süresi

63.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: MMQ 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.1 yıldır).

Mind Medicine (MindMed) Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Mind Medicine (MindMed) Inc. Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

Mindmed Appoints Stephanie Fagan as Chief Corporate Affairs Officer

Mind Medicine (MindMed) Inc., Annual General Meeting, Jun 10, 2024

Chief Financial Officer recently sold €71k worth of stock

Mind Medicine (Mindmed) Inc. Elects David Gryska to the Board of Directors

Mind Medicine (MindMed) Inc., Annual General Meeting, Jun 15, 2023

Recent updates

Mind Medicine (MindMed) Inc. Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

New major risk - Share price stability

Mind Medicine (Mindmed) Inc. Presents Phase 2B Study of Mm120 for Generalized Anxiety Disorder (Gad) At American Psychiatric Association

Mind Medicine (MindMed) Inc. has completed a Follow-on Equity Offering in the amount of $74.998573 million.

Mind Medicine (MindMed) Inc. has filed a Follow-on Equity Offering.

Mind Medicine (MindMed) Inc. to Report Q2, 2024 Results on Aug 13, 2024

Mind Medicine (MindMed) Inc. to Report Q2, 2024 Results on Aug 13, 2024

Mindmed Appoints Stephanie Fagan as Chief Corporate Affairs Officer

Mind Medicine (MindMed) Inc. Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)

Mind Medicine (MindMed) Inc.(NasdaqGS:MNMD) dropped from Russell 3000E Value Index

Mind Medicine (MindMed) Inc Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)

Mind Medicine (MindMed) Inc., Annual General Meeting, Jun 10, 2024

Numinus Wellness Congratulates Mindmed on Positive Results from Phase 2B Clinical Trials of Mm120 for Generalized Anxiety Disorder

New major risk - Shareholder dilution

Mind Medicine (MindMed) Inc. has completed a Follow-on Equity Offering in the amount of $100.000002 million.

Mind Medicine (MindMed) Inc. has completed a Follow-on Equity Offering in the amount of $100.000002 million.

Mind Medicine (Mindmed) Inc. Provides Anticipated Production Milestones for 2024

Mind Medicine Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Mind Medicine (MindMed) Inc. Completes Enrollment of Phase 2A Trial of Mm-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)

Mind Medicine Completes Enrollment and Dosing in Study Mmed008

Chief Financial Officer recently sold €71k worth of stock

Mind Medicine (Mindmed) Inc. Elects David Gryska to the Board of Directors

FCM MM Holdings Posts Material on Social Media Platforms

FCM MM Holdings Calls for Socially Responsible Investors to Vote for Change at Mind Medicine

FCM MM Holdings Posts Material on Twitter

FCM MM Holdings Provides Information to Shareholders of Mind Medicine

FCM MM Holdings Condemns the Report Issued by Institutional Shareholder Services

FCM MM Holdings LLC Issues a Letter to the Shareholders of Mind Medicine Inc

FCM MM Holdings Posts Materials to Reddit

FCM MM Holdings Sends Letter to Shareholders of Mind Medicine (MindMed)

Mind Medicine Posts Materials to Twitter

FCM MM Holdings Issues an Investor Presentation to Shareholders of Mind Medicine

Mind Medicine (MindMed) Inc. Enters into Phase 2b Clinical Trial Evaluating MM-120 (lysergide D-Tartrate) for GAD

FCM Director Nominees Will Put MindMed Drug Development Process Back on Track

Mind Medicine Launches a Website and Post the Materials

Mind Medicine (MindMed) Inc., Annual General Meeting, Jun 15, 2023

High number of new and inexperienced directors

FCM MM Holdings LLC Sends a Letter to Mind Medicine (MindMed) Inc

FCM MM HOLDINGS, LLC Demands Federal Investigation to Probe Serious Allegations of Misconduct at Mind Medicine (MindMed) Inc

Mind Medicine Announces Initiation of Phase 1 Comparative PK/PD Trial of R-, S- and Racemic MDMA

FCM MM HOLDINGS Sends Letter to the Board of Mind Medicine

Mind Medicine (MindMed) Inc. Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances

Mind Medicine Regains Compliance with Nasdaq's Minimum Bid Price Listing Requirement

Mind Medicine (MindMed) Inc. Announces Positive Results from Collaborators' Placebo-Controlled Investigator-Initiated Trial Published in Peer-Reviewed Journal

Mind Medicine (MindMed) Inc. Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

Mind Medicine (MindMed) Inc. Announces Board Appointments

Mind Medicine (MindMed) Receives Non-Compliance Letter from Nasdaq

Mind Medicine (MindMed) Inc. Appoints Schond L. Greenway as Chief Financial Officer

Mind Medicine (MindMed) Inc Reports Topline Data from Phase 1 Trial of MM-110 in Development for Treatment of Opioid Withdrawal

Mind Medicine (MindMed) Inc Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders

High number of new and inexperienced directors

Mind Medicine (MindMed) Inc. Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for Lsd in Anxiety Disorders At Psych Symposium

Mind Medicine (MindMed) Inc. Appoints Francois Lilienthal as Chief Commercial Officer

Mindmed Announces Publication of Study Comparing the Acute Effects of Lysergic Acid Diethylamide and Psilocybin in Healthy Subjects

Mindmed Announces Publication of Study Comparing the Acute Effects of Lysergic Acid Diethylamide and Psilocybin in Healthy Subjects

U.S. Food and Drug Administration Clears Mind Medicine (MindMed) Inc.'s Investigational New Drug for MM-120 in Treatment of Generalized Anxiety Disorder

Mind Medicine (MindMed) Inc. Enrolls the First Subjects into Its Session Monitoring System

Mind Medicine (MindMed) Inc. Successfully Completes Phase 1 Clinical Trial of 18-MC

Mind Medicine (Mindmed) Inc. Provides Status Update on Ind for Phase 2B Trial of LSD for the Treatment of Generalized Anxiety Disorder

Mind Medicine (MindMed) Inc. Initiates Phase 2a LSD Trial for the Treatment of Adult ADHD

Chief Financial Officer recently sold €154k worth of stock

Chairman of the Board of Directors recently sold €669k worth of stock

Less than half of directors are independent

Co-Founder & Director recently sold €2.3m worth of stock

Chairman of the Board of Directors recently sold €262k worth of stock

Independent Director recently sold €3.9m worth of stock

MindMed Announces the Publication of the First Pharmacogenetic Data on Lsd to Help Personalize Dosing